Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 182

1.

Update: Influenza Activity - United States and Worldwide, May 19-September 28, 2019, and Composition of the 2020 Southern Hemisphere Influenza Vaccine.

Epperson S, Davis CT, Brammer L, Abd Elal AI, Ajayi N, Barnes J, Budd AP, Burns E, Daly P, Dugan VG, Fry AM, Jang Y, Johnson SJ, Kniss K, Kondor R, Grohskopf LA, Gubareva L, Merced-Morales A, Sessions W, Stevens J, Wentworth DE, Xu X, Jernigan D.

MMWR Morb Mortal Wkly Rep. 2019 Oct 11;68(40):880-884. doi: 10.15585/mmwr.mm6840a3.

2.

Replicative fitness of seasonal influenza A viruses with decreased susceptibility to baloxavir.

Chesnokov A, Patel MC, Mishin VP, De La Cruz JA, Lollis L, Nguyen HT, Dugan V, Wentworth DE, Gubareva LV.

J Infect Dis. 2019 Sep 21. pii: jiz472. doi: 10.1093/infdis/jiz472. [Epub ahead of print]

PMID:
31541547
3.

Baloxavir and Treatment-Emergent Resistance: Public Health Insights and Next Steps.

Gubareva LV, Fry AM.

J Infect Dis. 2019 Jul 16. pii: jiz245. doi: 10.1093/infdis/jiz245. [Epub ahead of print] No abstract available.

PMID:
31309982
4.

Susceptibility of Influenza A, B, C, and D Viruses to Baloxavir1.

Mishin VP, Patel MC, Chesnokov A, De La Cruz J, Nguyen HT, Lollis L, Hodges E, Jang Y, Barnes J, Uyeki T, Davis CT, Wentworth DE, Gubareva LV.

Emerg Infect Dis. 2019 Oct;25(10):1969-1972. doi: 10.3201/eid2510.190607. Epub 2019 Oct 17.

5.

Update: Influenza Activity in the United States During the 2018-19 Season and Composition of the 2019-20 Influenza Vaccine.

Xu X, Blanton L, Elal AIA, Alabi N, Barnes J, Biggerstaff M, Brammer L, Budd AP, Burns E, Cummings CN, Garg S, Kondor R, Gubareva L, Kniss K, Nyanseor S, O'Halloran A, Rolfes M, Sessions W, Dugan VG, Fry AM, Wentworth DE, Stevens J, Jernigan D.

MMWR Morb Mortal Wkly Rep. 2019 Jun 21;68(24):544-551. doi: 10.15585/mmwr.mm6824a3.

6.

Detection of oseltamivir-resistant zoonotic and animal influenza A viruses using the rapid influenza antiviral resistance test.

Hodges EN, Mishin VP, De la Cruz J, Guo Z, Nguyen HT, Fallows E, Stevens J, Wentworth DE, Davis CT, Gubareva LV.

Influenza Other Respir Viruses. 2019 Jun 11. doi: 10.1111/irv.12661. [Epub ahead of print]

7.

Insights into the antigenic advancement of influenza A(H3N2) viruses, 2011-2018.

Jorquera PA, Mishin VP, Chesnokov A, Nguyen HT, Mann B, Garten R, Barnes J, Hodges E, De La Cruz J, Xu X, Katz J, Wentworth DE, Gubareva LV.

Sci Rep. 2019 Feb 25;9(1):2676. doi: 10.1038/s41598-019-39276-1.

8.

Update: Influenza Activity - United States, September 30, 2018-February 2, 2019.

Blanton L, Dugan VG, Abd Elal AI, Alabi N, Barnes J, Brammer L, Budd AP, Burns E, Cummings CN, Garg S, Garten R, Gubareva L, Kniss K, Kramer N, O'Halloran A, Reed C, Rolfes M, Sessions W, Taylor C, Xu X, Fry AM, Wentworth DE, Katz J, Jernigan D.

MMWR Morb Mortal Wkly Rep. 2019 Feb 15;68(6):125-134. doi: 10.15585/mmwr.mm6806a1.

9.

Assessing baloxavir susceptibility of influenza viruses circulating in the United States during the 2016/17 and 2017/18 seasons.

Gubareva LV, Mishin VP, Patel MC, Chesnokov A, Nguyen HT, De La Cruz J, Spencer S, Campbell AP, Sinner M, Reid H, Garten R, Katz JM, Fry AM, Barnes J, Wentworth DE.

Euro Surveill. 2019 Jan;24(3). doi: 10.2807/1560-7917.ES.2019.24.3.1800666.

10.

Influenza Activity - United States, September 30-December 1, 2018.

Budd AP, Abd Elal AI, Alabi N, Barnes J, Blanton L, Brammer L, Burns E, Cummings CN, Dugan VG, Garg S, Garten R, Grohskopf LA, Gubareva L, Kniss K, Kramer N, O'Halloran A, Sessions W, Taylor C, Wentworth DE, Xu X, Fry AM, Katz J, Jernigan D.

MMWR Morb Mortal Wkly Rep. 2018 Dec 14;67(49):1369-1371. doi: 10.15585/mmwr.mm6749a4.

11.

Update: Influenza Activity - United States and Worldwide, May 20-October 13, 2018.

Chow EJ, Davis CT, Abd Elal AI, Alabi N, Azziz-Baumgartner E, Barnes J, Blanton L, Brammer L, Budd AP, Burns E, Davis WW, Dugan VG, Fry AM, Garten R, Grohskopf LA, Gubareva L, Jang Y, Jones J, Kniss K, Lindstrom S, Mustaquim D, Porter R, Rolfes M, Sessions W, Taylor C, Wentworth DE, Xu X, Zanders N, Katz J, Jernigan D.

MMWR Morb Mortal Wkly Rep. 2018 Oct 26;67(42):1178-1185. doi: 10.15585/mmwr.mm6742a3.

12.

Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors and status of novel antivirals, 2016-2017.

Lackenby A, Besselaar TG, Daniels RS, Fry A, Gregory V, Gubareva LV, Huang W, Hurt AC, Leang SK, Lee RTC, Lo J, Lollis L, Maurer-Stroh S, Odagiri T, Pereyaslov D, Takashita E, Wang D, Zhang W, Meijer A.

Antiviral Res. 2018 Sep;157:38-46. doi: 10.1016/j.antiviral.2018.07.001. Epub 2018 Jul 3.

13.

Update: Influenza Activity in the United States During the 2017-18 Season and Composition of the 2018-19 Influenza Vaccine.

Garten R, Blanton L, Elal AIA, Alabi N, Barnes J, Biggerstaff M, Brammer L, Budd AP, Burns E, Cummings CN, Davis T, Garg S, Gubareva L, Jang Y, Kniss K, Kramer N, Lindstrom S, Mustaquim D, O'Halloran A, Sessions W, Taylor C, Xu X, Dugan VG, Fry AM, Wentworth DE, Katz J, Jernigan D.

MMWR Morb Mortal Wkly Rep. 2018 Jun 8;67(22):634-642. doi: 10.15585/mmwr.mm6722a4.

14.

Mapping of the US Domestic Influenza Virologic Surveillance Landscape.

Jester B, Schwerzmann J, Mustaquim D, Aden T, Brammer L, Humes R, Shult P, Shahangian S, Gubareva L, Xu X, Miller J, Jernigan D.

Emerg Infect Dis. 2018 Jul;24(7). doi: 10.3201/eid2407.180028. Epub 2018 Jul 17.

15.

Susceptibility of Brazilian influenza A(H1N1)pdm09 viruses to neuraminidase inhibitors in the 2014-2016 seasons: Identification of strains bearing mutations associated with reduced inhibition profile.

Matos AR, Resende PC, Miranda MD, Garcia CC, Caetano BC, Lopes JCO, Debur MC, Cury ALF, Vianna LA, Lima MC, Schirmer M, Gubareva L, Hurt AC, Brown DW, Siqueira MM.

Antiviral Res. 2018 Jun;154:35-43. doi: 10.1016/j.antiviral.2018.03.010. Epub 2018 Mar 28.

PMID:
29601892
16.

Update: Influenza Activity - United States, October 1, 2017-February 3, 2018.

Budd AP, Wentworth DE, Blanton L, Elal AIA, Alabi N, Barnes J, Brammer L, Burns E, Cummings CN, Davis T, Flannery B, Fry AM, Garg S, Garten R, Gubareva L, Jang Y, Kniss K, Kramer N, Lindstrom S, Mustaquim D, O'Halloran A, Olsen SJ, Sessions W, Taylor C, Xu X, Dugan VG, Katz J, Jernigan D.

MMWR Morb Mortal Wkly Rep. 2018 Feb 16;67(6):169-179. doi: 10.15585/mmwr.mm6706a1.

17.

Update: Influenza Activity - United States, October 1-November 25, 2017.

Dugan VG, Blanton L, Elal AIA, Alabi N, Barnes J, Brammer L, Burns E, Cummings CN, Davis T, Flannery B, Fry AM, Garg S, Garten R, Gubareva L, Jang Y, Kniss K, Kramer N, Lindstrom S, Mustaquim D, O'Halloran A, Olsen SJ, Sessions W, Taylor C, Trock S, Xu X, Wentworth DE, Katz J, Jernigan D.

MMWR Morb Mortal Wkly Rep. 2017 Dec 8;66(48):1318-1326. doi: 10.15585/mmwr.mm6648a2.

18.

Avian Influenza A(H7N2) Virus in Human Exposed to Sick Cats, New York, USA, 2016.

Marinova-Petkova A, Laplante J, Jang Y, Lynch B, Zanders N, Rodriguez M, Jones J, Thor S, Hodges E, De La Cruz JA, Belser J, Yang H, Carney P, Shu B, Berman L, Stark T, Barnes J, Havers F, Yang P, Trock SC, Fry A, Gubareva L, Bresee JS, Stevens J, Daskalakis D, Liu D, Lee CT, Torchetti MK, Newbury S, Cigel F, Toohey-Kurth K, St George K, Wentworth DE, Lindstrom S, Davis CT.

Emerg Infect Dis. 2017 Dec;23(12). doi: 10.3201/eid2312.170798.

19.

The Household Influenza Vaccine Effectiveness Study: Lack of Antibody Response and Protection Following Receipt of 2014-2015 Influenza Vaccine.

Petrie JG, Malosh RE, Cheng CK, Ohmit SE, Martin ET, Johnson E, Truscon R, Eichelberger MC, Gubareva LV, Fry AM, Monto AS.

Clin Infect Dis. 2017 Oct 30;65(10):1644-1651. doi: 10.1093/cid/cix608.

20.

Update: Influenza Activity - United States and Worldwide, May 21-September 23, 2017.

Blanton L, Wentworth DE, Alabi N, Azziz-Baumgartner E, Barnes J, Brammer L, Burns E, Davis CT, Dugan VG, Fry AM, Garten R, Grohskopf LA, Gubareva L, Kniss K, Lindstrom S, Mustaquim D, Olsen SJ, Roguski K, Taylor C, Trock S, Xu X, Katz J, Jernigan D.

MMWR Morb Mortal Wkly Rep. 2017 Oct 6;66(39):1043-1051. doi: 10.15585/mmwr.mm6639a3.

21.

Highly Pathogenic Avian Influenza A(H5N1) Viruses at the Animal-Human Interface in Vietnam, 2003-2010.

Creanga A, Hang NLK, Cuong VD, Nguyen HT, Phuong HVM, Thanh LT, Thach NC, Hien PT, Tung N, Jang Y, Balish A, Dang NH, Duong MT, Huong NT, Hoa DN, Tho ND, Klimov A, Kapella BK, Gubareva L, Kile JC, Hien NT, Mai LQ, Davis CT.

J Infect Dis. 2017 Sep 15;216(suppl_4):S529-S538. doi: 10.1093/infdis/jix003.

PMID:
28934457
22.

Drug Susceptibility Evaluation of an Influenza A(H7N9) Virus by Analyzing Recombinant Neuraminidase Proteins.

Gubareva LV, Sleeman K, Guo Z, Yang H, Hodges E, Davis CT, Baranovich T, Stevens J.

J Infect Dis. 2017 Sep 15;216(suppl_4):S566-S574. doi: 10.1093/infdis/jiw625.

PMID:
28934455
23.

Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2015-2016.

Gubareva LV, Besselaar TG, Daniels RS, Fry A, Gregory V, Huang W, Hurt AC, Jorquera PA, Lackenby A, Leang SK, Lo J, Pereyaslov D, Rebelo-de-Andrade H, Siqueira MM, Takashita E, Odagiri T, Wang D, Zhang W, Meijer A.

Antiviral Res. 2017 Oct;146:12-20. doi: 10.1016/j.antiviral.2017.08.004. Epub 2017 Aug 10.

24.

Update: Influenza Activity in the United States During the 2016-17 Season and Composition of the 2017-18 Influenza Vaccine.

Blanton L, Alabi N, Mustaquim D, Taylor C, Kniss K, Kramer N, Budd A, Garg S, Cummings CN, Chung J, Flannery B, Fry AM, Sessions W, Garten R, Xu X, Elal AIA, Gubareva L, Barnes J, Dugan V, Wentworth DE, Burns E, Katz J, Jernigan D, Brammer L.

MMWR Morb Mortal Wkly Rep. 2017 Jun 30;66(25):668-676. doi: 10.15585/mmwr.mm6625a3.

25.

Monitoring influenza virus susceptibility to oseltamivir using a new rapid assay, iART.

Gubareva LV, Fallows E, Mishin VP, Hodges E, Brooks A, Barnes J, Fry AM, Kramp W, Shively R, Wentworth DE, Weidemaier K, Jacobson R.

Euro Surveill. 2017 May 4;22(18). pii: 30529. doi: 10.2807/1560-7917.ES.2017.22.18.30529.

26.

Antiviral Drug-Resistant Influenza B Viruses Carrying H134N Substitution in Neuraminidase, Laos, February 2016.

Baranovich T, Vongphrachanh P, Ketmayoon P, Sisouk T, Chomlasack K, Khanthamaly V, Nguyen HT, Mishin VP, Marjuki H, Barnes JR, Garten RJ, Stevens J, Wentworth DE, Gubareva LV.

Emerg Infect Dis. 2017 Apr;23(4):686-690. doi: 10.3201/eid2304.161876.

27.

Increase in Human Infections with Avian Influenza A(H7N9) Virus During the Fifth Epidemic - China, October 2016-February 2017.

Iuliano AD, Jang Y, Jones J, Davis CT, Wentworth DE, Uyeki TM, Roguski K, Thompson MG, Gubareva L, Fry AM, Burns E, Trock S, Zhou S, Katz JM, Jernigan DB.

MMWR Morb Mortal Wkly Rep. 2017 Mar 10;66(9):254-255. doi: 10.15585/mmwr.mm6609e2.

28.

Update: Influenza Activity - United States, October 2, 2016-February 4, 2017.

Blanton L, Mustaquim D, Alabi N, Kniss K, Kramer N, Budd A, Garg S, Cummings CN, Fry AM, Bresee J, Sessions W, Garten R, Xu X, Elal AI, Gubareva L, Barnes J, Wentworth DE, Burns E, Katz J, Jernigan D, Brammer L.

MMWR Morb Mortal Wkly Rep. 2017 Feb 17;66(6):159-166. doi: 10.15585/mmwr.mm6606a2.

29.

Quantification of Influenza Neuraminidase Activity by Ultra-High Performance Liquid Chromatography and Isotope Dilution Mass Spectrometry.

Solano MI, Woolfitt AR, Williams TL, Pierce CL, Gubareva LV, Mishin V, Barr JR.

Anal Chem. 2017 Mar 7;89(5):3130-3137. doi: 10.1021/acs.analchem.6b04902. Epub 2017 Feb 21.

30.

Update: Influenza Activity - United States, October 2-December 17, 2016.

Shang M, Blanton L, Kniss K, Mustaquim D, Alabi N, Barnes S, Budd A, Davlin SL, Kramer N, Garg S, Cummings CN, Flannery B, Fry AM, Grohskopf LA, Olsen SJ, Bresee J, Sessions W, Garten R, Xu X, Elal AI, Gubareva L, Barnes J, Wentworth DE, Burns E, Katz J, Jernigan D, Brammer L.

MMWR Morb Mortal Wkly Rep. 2016 Dec 30;65(50-51):1439-1444. doi: 10.15585/mmwr.mm655051a5.

31.

A Pyrosequencing-Based Approach to High-Throughput Identification of Influenza A(H3N2) Virus Clades Harboring Antigenic Drift Variants.

Mishin VP, Baranovich T, Garten R, Chesnokov A, Abd Elal AI, Adamczyk M, LaPlante J, St George K, Fry AM, Barnes J, Chester SC, Xu X, Katz JM, Wentworth DE, Gubareva LV.

J Clin Microbiol. 2016 Dec 28;55(1):145-154. doi: 10.1128/JCM.01840-16. Print 2017 Jan.

32.

Update: Influenza Activity - United States and Worldwide, May 22-September 10, 2016.

Budd A, Blanton L, Kniss K, Smith S, Mustaquim D, Davlin SL, Kramer N, Flannery B, Fry AM, Grohskopf LA, Olsen SJ, Bresee J, Sessions W, Garten R, Xu X, Elal AI, Gubareva L, Barnes J, Wentworth DE, Burns E, Katz J, Jernigan D, Brammer L.

MMWR Morb Mortal Wkly Rep. 2016 Sep 23;65(37):1008-1014. doi: 10.15585/mmwr.mm6537a5.

33.

Human Monoclonal Antibody 81.39a Effectively Neutralizes Emerging Influenza A Viruses of Group 1 and 2 Hemagglutinins.

Marjuki H, Mishin VP, Chai N, Tan MW, Newton EM, Tegeris J, Erlandson K, Willis M, Jones J, Davis T, Stevens J, Gubareva LV.

J Virol. 2016 Nov 14;90(23):10446-10458. doi: 10.1128/JVI.01284-16. Print 2016 Dec 1.

34.

A randomized, double-blind, placebo-controlled trial evaluating the safety of early oseltamivir treatment among children 0-9 years of age hospitalized with influenza in El Salvador and Panama.

Dawood FS, Jara J, Gonzalez R, Castillo JM, De León T, Estripeaut D, Luciani K, Sujey Brizuela Y, Barahona A, Cazares RA, Lawson AM, Rodriguez M, de Viana D, Franco D, Castillo M, Fry AM, Gubareva L, Tamura D, Hughes M, Gargiullo P, Clara W, Azziz-Baumgartner E, Widdowson MA.

Antiviral Res. 2016 Sep;133:85-94. doi: 10.1016/j.antiviral.2016.07.007. Epub 2016 Jul 21.

PMID:
27451343
35.

Influenza Activity - United States, 2015-16 Season and Composition of the 2016-17 Influenza Vaccine.

Davlin SL, Blanton L, Kniss K, Mustaquim D, Smith S, Kramer N, Cohen J, Cummings CN, Garg S, Flannery B, Fry AM, Grohskopf LA, Bresee J, Wallis T, Sessions W, Garten R, Xu X, Elal AI, Gubareva L, Barnes J, Wentworth DE, Burns E, Katz J, Jernigan D, Brammer L.

MMWR Morb Mortal Wkly Rep. 2016 Jun 10;65(22):567-75. doi: 10.15585/mmwr.mm6522a3.

36.

Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2014-2015.

Hurt AC, Besselaar TG, Daniels RS, Ermetal B, Fry A, Gubareva L, Huang W, Lackenby A, Lee RT, Lo J, Maurer-Stroh S, Nguyen HT, Pereyaslov D, Rebelo-de-Andrade H, Siqueira MM, Takashita E, Tashiro M, Tilmanis D, Wang D, Zhang W, Meijer A.

Antiviral Res. 2016 Aug;132:178-85. doi: 10.1016/j.antiviral.2016.06.001. Epub 2016 Jun 3. Review.

37.

Enhanced Genetic Characterization of Influenza A(H3N2) Viruses and Vaccine Effectiveness by Genetic Group, 2014-2015.

Flannery B, Zimmerman RK, Gubareva LV, Garten RJ, Chung JR, Nowalk MP, Jackson ML, Jackson LA, Monto AS, Ohmit SE, Belongia EA, McLean HQ, Gaglani M, Piedra PA, Mishin VP, Chesnokov AP, Spencer S, Thaker SN, Barnes JR, Foust A, Sessions W, Xu X, Katz J, Fry AM.

J Infect Dis. 2016 Oct 1;214(7):1010-9. doi: 10.1093/infdis/jiw181. Epub 2016 May 6. Erratum in: J Infect Dis. 2017 Jun 1;215(11):1774.

38.

Molecular Characterizations of Surface Proteins Hemagglutinin and Neuraminidase from Recent H5Nx Avian Influenza Viruses.

Yang H, Carney PJ, Mishin VP, Guo Z, Chang JC, Wentworth DE, Gubareva LV, Stevens J.

J Virol. 2016 May 27;90(12):5770-5784. doi: 10.1128/JVI.00180-16. Print 2016 Jun 15.

39.

Update: Influenza Activity--United States, October 4, 2015-February 6, 2016.

Russell K, Blanton L, Kniss K, Mustaquim D, Smith S, Cohen J, Garg S, Flannery B, Fry AM, Grohskopf LA, Bresee J, Wallis T, Sessions W, Garten R, Xu X, Elal AI, Gubareva L, Barnes J, Wentworth DE, Burns E, Katz J, Jernigan D, Brammer L.

MMWR Morb Mortal Wkly Rep. 2016 Feb 19;65(6):146-53. doi: 10.15585/mmwr.mm6506a3.

40.

Standardizing the influenza neuraminidase inhibition assay among United States public health laboratories conducting virological surveillance.

Okomo-Adhiambo M, Mishin VP, Sleeman K, Saguar E, Guevara H, Reisdorf E, Griesser RH, Spackman KJ, Mendenhall M, Carlos MP, Healey B, St George K, Laplante J, Aden T, Chester S, Xu X, Gubareva LV.

Antiviral Res. 2016 Apr;128:28-35. doi: 10.1016/j.antiviral.2016.01.009. Epub 2016 Jan 22.

PMID:
26808479
41.

Update: Influenza Activity - United States.

Smith S, Blanton L, Kniss K, Mustaquim D, Steffens C, Reed C, Bramley A, Flannery B, Fry AM, Grohskopf LA, Bresee J, Wallis T, Garten R, Xu X, Elal AI, Gubareva L, Barnes J, Wentworth DE, Burns E, Katz J, Jernigan D, Brammer L.

MMWR Morb Mortal Wkly Rep. 2015 Dec 11;64(48):1342-8. doi: 10.15585/mmwr.mm6448a4.

42.

Update: Influenza Activity--United States and Worldwide, May 24-September 5, 2015.

Blanton L, Kniss K, Smith S, Mustaquim D, Steffens C, Flannery B, Fry AM, Bresee J, Wallis T, Garten R, Xu X, Elal AI, Gubareva L, Wentworth DE, Burns E, Katz J, Jernigan D, Brammer L.

MMWR Morb Mortal Wkly Rep. 2015 Sep 18;64(36):1011-6. doi: 10.15585/mmwr.mm6436a4.

43.

Detection and Characterization of Clade 1 Reassortant H5N1 Viruses Isolated from Human Cases in Vietnam during 2013.

Thor SW, Nguyen H, Balish A, Hoang AN, Gustin KM, Nhung PT, Jones J, Thu NN, Davis W, Ngoc TN, Jang Y, Sleeman K, Villanueva J, Kile J, Gubareva LV, Lindstrom S, Tumpey TM, Davis CT, Long NT.

PLoS One. 2015 Aug 5;10(8):e0133867. doi: 10.1371/journal.pone.0133867. eCollection 2015.

44.

Influenza activity - United States, 2014-15 season and composition of the 2015-16 influenza vaccine.

Appiah GD, Blanton L, D'Mello T, Kniss K, Smith S, Mustaquim D, Steffens C, Dhara R, Cohen J, Chaves SS, Bresee J, Wallis T, Xu X, Abd Elal AI, Gubareva L, Wentworth DE, Katz J, Jernigan D, Brammer L; Centers for Disease Control and Prevention (CDC).

MMWR Morb Mortal Wkly Rep. 2015 Jun 5;64(21):583-90.

45.

Emergence of Multidrug-Resistant Influenza A(H1N1)pdm09 Virus Variants in an Immunocompromised Child Treated With Oseltamivir and Zanamivir.

Tamura D, DeBiasi RL, Okomo-Adhiambo M, Mishin VP, Campbell AP, Loechelt B, Wiedermann BL, Fry AM, Gubareva LV.

J Infect Dis. 2015 Oct 15;212(8):1209-13. doi: 10.1093/infdis/jiv245. Epub 2015 May 5.

PMID:
25943200
46.

Effects of oseltamivir treatment of index patients with influenza on secondary household illness in an urban setting in Bangladesh: secondary analysis of a randomised, placebo-controlled trial.

Fry AM, Goswami D, Nahar K, Sharmin AT, Rahman M, Gubareva L, Trujillo A, Barnes J, Azim T, Bresee J, Luby SP, Brooks WA.

Lancet Infect Dis. 2015 Jun;15(6):654-62. doi: 10.1016/S1473-3099(15)70041-1. Epub 2015 Mar 16.

PMID:
25788164
47.

Update: Influenza activity--United States, September 28, 2014-February 21, 2015.

D'Mello T, Brammer L, Blanton L, Kniss K, Smith S, Mustaquim D, Steffens C, Dhara R, Cohen J, Chaves SS, Finelli L, Bresee J, Wallis T, Xu X, Abd Elal AI, Gubareva L, Wentworth D, Villanueva J, Katz J, Jernigan D; Centers for Disease Control and Prevention (CDC).

MMWR Morb Mortal Wkly Rep. 2015 Mar 6;64(8):206-12.

48.

Neuraminidase Mutations Conferring Resistance to Oseltamivir in Influenza A(H7N9) Viruses.

Marjuki H, Mishin VP, Chesnokov AP, De La Cruz JA, Davis CT, Villanueva JM, Fry AM, Gubareva LV.

J Virol. 2015 May;89(10):5419-26. doi: 10.1128/JVI.03513-14. Epub 2015 Mar 4.

49.

Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2013-2014.

Takashita E, Meijer A, Lackenby A, Gubareva L, Rebelo-de-Andrade H, Besselaar T, Fry A, Gregory V, Leang SK, Huang W, Lo J, Pereyaslov D, Siqueira MM, Wang D, Mak GC, Zhang W, Daniels RS, Hurt AC, Tashiro M.

Antiviral Res. 2015 May;117:27-38. doi: 10.1016/j.antiviral.2015.02.003. Epub 2015 Feb 23.

50.

Application of a seven-target pyrosequencing assay to improve the detection of neuraminidase inhibitor-resistant Influenza A(H3N2) viruses.

Tamura D, Okomo-Adhiambo M, Mishin VP, Guo Z, Xu X, Villanueva J, Fry AM, Stevens J, Gubareva LV.

Antimicrob Agents Chemother. 2015 Apr;59(4):2374-9. doi: 10.1128/AAC.04939-14. Epub 2015 Feb 2.

Supplemental Content

Loading ...
Support Center